Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Completed · Phase 1/Phase 2

Conditions studied: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

In brief

This is a phase I/II study of the combination of etanercept and rituximab in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This combination is proposed to improve the efficacy and diminish the toxicity of this the

Key facts

Study ID

NCT00201682

Run by

John Byrd

People needed

36

Starts

2002-10-01

Expected to finish

2009-08-01

Last updated by the study team

2017-02-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must have been previously treated CLL/SLL
• Must have CD20 expression
• ECOG PS =<3
• No prior Campath-1H
• No active infection requiring antibiotics
• No concurrent immunosuppressive therapy
• No prior history demyelinating neurologic disease
• No active viral hepatitis

You may not qualify if…

• No pregnant or breastfeeding women
• ECOG PS =4
• Life expectancy of >12 weeks
• Patients with bilirubin or creatinine>3.0 mg/dl

Where it is running

• Ohio State University Medical Center — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.